Log In
Print
BCIQ
Print
Print this Print this
 

AKB-6548

  Manage Alerts
Collapse Summary General Information
Company Akebia Therapeutics Inc.
DescriptionOral hypoxia-inducible factor prolyl hydroxylase (HIF-PH; EGLN) inhibitor
Molecular Target Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) (EGLN)
Mechanism of ActionHypoxia-inducible factor prolyl hydroxylase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationAnemia
Indication DetailsTreat anemia; Treat anemia in patients with chronic kidney disease (CKD)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today